Coordinating Minister for Economic Affairs of Indonesia, Airlangga Hartarto, and French Minister for the Economy, Finance and Industrial and Digital Sovereignty, Eric Lombard, witness the signing of a strategic Memorandum of Understanding for vaccine collaboration by the representatives from PT Bio Farma, BioNet Europe and BioNet Asia at the Indonesia–France Business Forum 2025 in Jakarta.
Jakarta, May 28, 2025 — BioNet, a Franco-Thai vaccine biotech group, and PT Bio Farma (Persero), Indonesia’s state-owned vaccine manufacturer, have signed a Memorandum of Understanding (MoU) to collaborate on the development and regional distribution of a combined TdaP vaccine (tetanus, diphtheria, and acellular recombinant pertussis).
Signed during the State Visit of French President Emmanuel Macron to Indonesia, the agreement underscores a shared commitment to accelerating access to innovative vaccines across Southeast Asia. The partnership combines BioNet’s proprietary recombinant pertussis technology and global clinical development experience with Bio Farma’s large-scale manufacturing capabilities and public health reach to address critical immunization needs in ASEAN.
“This agreement reflects our shared vision to make next-generation vaccines more accessible where they are most needed,” said Philippe Guillot-Chêne, CEO of BioNet Europe. “By aligning our strengths, BioNet and Bio Farma are helping to build a stronger regional health ecosystem and reinforce ASEAN’s capacity to respond to both current and emerging infectious disease threats.”
The MoU outlines cooperation in clinical development, regulatory alignment, and market access strategies. Bio Farma will conduct clinical trials and manage regulatory submissions in Indonesia, while BioNet will do so in other ASEAN countries. The collaboration aims to accelerate vaccine availability by reducing the time gap in introducing innovative vaccines to the region—from 10–15 years down to less than five.
“Through this collaboration, we are reinforcing Indonesia’s commitment to regional vaccine self-sufficiency and innovation,” said Yuliana Indriati, Director of Business Development at Bio Farma. “With BioNet’s advanced recombinant pertussis technology and our production capacity, we aim to ensure timely access to TdaP vaccines for Indonesian adolescents, pregnant women, and the elderly. We hope this product will soon be part of our national immunization program.”
The TdaP vaccine developed under this partnership will leverage antigens contributed by both parties—Td from Bio Farma and aP from BioNet. The combined product is targeted for use across ASEAN, with a potential market of 10–15 million doses annually, valued at around USD 200 million.
This collaboration is expected to help strengthen regional pandemic preparedness, build resilient vaccine supply chains, and promote equitable health access across Southeast Asia.
This step is in line with President Prabowo Subianto’s Asta Cita, particularly the goals of realizing national self-reliance in the fields of economy, food, and energy, as well as improving the quality of life of the people and expanding access to affordable and high-quality healthcare services.
About BioNet
BioNet is a French-Thai vaccine organization developing and manufacturing genetically designed vaccines with a global footprint. The group includes:
- BioNet Europe, a fast-growing French biotech company which has recently submitted an EU-GMP certified recombinant pertussis vaccine application to the European Medicines Agency (EMA) for centralized approval.
- BioNet Asia, a leading vaccine company based in Thailand, producing and marketing a range of vaccines that include the world’s only recombinant pertussis standalone vaccine.
BioNet has also developed a clinically-proven, end-to-end mRNA production process, enabling multiple collaborations with leading organizations and academic institutions worldwide to promote technology transfer, regional manufacturing, and pandemic preparedness.
About Bio Farma
PT Bio Farma (Persero) is Indonesia’s largest state-owned pharmaceutical holding company, operating in the healthcare sector with integrated end-to-end services — ranging from pharmaceutical research and development, manufacturing, and distribution to retail pharmacy operations, clinics, and clinical laboratories.To support its business operations, Bio Farma operates a head office and manufacturing facility in Bandung, West Java, which includes office buildings and production facilities. The company also maintains a representative office in Jakarta. With an annual production capacity of over 3.2 billion doses of vaccine, Bio Farma exports its products to more than 150 countries worldwide. It serves as the parent company of two publicly listed pharmaceutical companies on the Indonesia Stock Exchange (IDX): PT Kimia Farma Tbk (KAEF) and PT Indofarma Tbk (INAF). For more information, please visit: www.biofarma.co.id.
For press information, kindly contact:
PT Bio Farma (Persero)
Zaki Zakaria
Corporate Communication
corcom@biofarma.co.id
BioNet Europe
Pierre Jean-François
pierre@bionet-asia.com
www.bionet.one
BioNet Asia
Supachai Nampornchaisakul
supachai.n@bionet-asia.com
www.bionet-asia.com
